Phaseline

Targets › HLA-DPB1

HLA-DPB1 (HLA class II histocompatibility antigen, DP beta 1 chain): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Hematology, Other; next expected readout Jul 2027.

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. (UniProt, P04440)

Open in Phaseline: the race on HLA-DPB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nantes University HospitalCTL 19
HLA-DPB1-specific T cell clone therapy targeting HLA-DPB1*04:01 expressing hematological m
HLA-DPB1Phase 3Ankle Fractures; Haematologic DiseaseJul 2027

Conditions

Ankle Fractures (1) Haematologic Disease (1)

Modalities

other (1)

Companies

Nantes University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.